Evidence map›Paper›PMID 40023227›Full record

ArticleJournal of controlled release : official journal of the Controlled Release Society2025

Timely administration of drug combination improves chemoimmunotherapy of an immune-cold tumor.

Fanfei Meng, Yanying He, Jiaqi Zhao, Zhongyue Yuan, Jianping Wang, Karen Gutierrez Parra, Melissa L Fishel, Timothy L Ratliff, Yoon Yeo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of controlled release : official journal of the Controlled Release Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Fanfei MengDepartment of Industrial and Molecular Pharmaceutics, Purdue University, 575 Stadium Mall Drive, West Lafayette, IN 47907, USA; Department of Biomedical and Nutritional Sciences, University of Massachusetts Lowell, 3 Solomont Way, Lowell, MA 01854, USA.
Yanying HeDepartment of Industrial and Molecular Pharmaceutics, Purdue University, 575 Stadium Mall Drive, West Lafayette, IN 47907, USA.
Jiaqi ZhaoDepartment of Industrial and Molecular Pharmaceutics, Purdue University, 575 Stadium Mall Drive, West Lafayette, IN 47907, USA.
Zhongyue YuanDepartment of Industrial and Molecular Pharmaceutics, Purdue University, 575 Stadium Mall Drive, West Lafayette, IN 47907, USA.
Jianping WangDepartment of Industrial and Molecular Pharmaceutics, Purdue University, 575 Stadium Mall Drive, West Lafayette, IN 47907, USA.
Karen Gutierrez ParraDepartment of Industrial and Molecular Pharmaceutics, Purdue University, 575 Stadium Mall Drive, West Lafayette, IN 47907, USA.
Melissa L FishelDepartments of Pediatrics and of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
Timothy L RatliffPurdue University Institute for Cancer Research, 201 South University Street, West Lafayette, IN 47907, USA; Department of Comparative Pathobiology, Purdue University, 625 Harrison Street, West Lafayette, Indiana 47907, USA.
Yoon YeoDepartment of Industrial and Molecular Pharmaceutics, Purdue University, 575 Stadium Mall Drive, West Lafayette, IN 47907, USA; Purdue University Institute for Cancer Research, 201 South University Street, West Lafayette, IN 47907, USA; Weldon School of Biomedical Engineering, Purdue University, 206 S Martin Jischke Drive, West Lafayette, IN 47907, USA. Electronic address: yyeo@purdue.edu.

Funding

Tumor Microenvironment and Metastasis ProgramP30CA082709 · NCI · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI Sara K Quinney · 1999 to 2026
$59.3M
Transgenic Mouse Core Facility Shared Resource (TMCF-SR)P30CA023168 · NCI · PURDUE UNIVERSITY WEST LAFAYETTE · PI Andrea L Kasinski · 1985 to 2026
$43.4M
Novel Role of Ref-1 in Pancreatic Cancer Etiology and ProgressionR01CA167291 · NCI · INDIANA UNIVERSITY INDIANAPOLIS · PI FISHEL, MELISSA L., KELLEY, MARK R. · 2013 to 2022
$5.2M
Reprogramming PDAC Stroma by Targeting Coagulation in the Tumor MicroenvironmentU01CA274304 · NCI · UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN · PI Melissa L. Fishel, Matthew J. Flick · 2022 to 2026
$4.6M
Targeting the Plasminogen Activation System to Limit Pancreatic Cancer Progression and Associated ThrombosisU01HL143403 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI FISHEL, MELISSA L., FLICK, MATTHEW J. · 2018 to 2022
$4.2M
Systemic delivery of siRNA by Nanosac for checkpoint blockade immunotherapy of head and neck squamous cell cancerR01CA258737 · NCI · PURDUE UNIVERSITY · PI KRON, STEPHEN J., YEO, YOON · 2021 to 2024
$2.3M
Investigation of novel signaling protein in 3D and in vivo PDAC models using second generation Ref-1 inhibitorsR01CA254110 · NCI · INDIANA UNIVERSITY INDIANAPOLIS · PI FISHEL, MELISSA L., HAN, BUMSOO · 2021 to 2025
$2.1M
Chemotherapy delivery with nanoparticles for targeted induction of immunogenic cell deathR01CA232419 · NCI · PURDUE UNIVERSITY · PI YEO, YOON · 2018 to 2022
$2.0M
A Fragment-Based Strategy for K-RAS Covalent InhibitorsR01CA264471 · NCI · UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN · PI MEROUEH, SAMY · 2021 to 2024
$1.9M
NCI NIH HHS P30 CA023168NCI NIH HHS P30 CA082709NCI NIH HHS R01 CA167291NCI NIH HHS R01 CA232419NCI NIH HHS R01 CA254110NCI NIH HHS R01 CA258737NCI NIH HHS R01 CA264471NCI NIH HHS U01 CA274304NHLBI NIH HHS U01 HL143403
6 · The paper itself

Abstract

An immunoactive complex consisting of a polyethyleneimine derivative (2E'), paclitaxel (PTX), and cyclic dinucleotide (CDN) was developed for chemoimmunotherapy of solid tumors. Each component uniquely contributes to stimulating innate immune response to tumors: 2E' carries PTX and CDN while stimulating antigen-presenting cells, PTX induces immunogenic cell death, and CDN activates the STING pathway. A single intratumoral injection of 2E'/PTX/CDN inhibited the growth of MOC1 oral squamous cell carcinoma and KPCY (2838c3) pancreatic tumors, achieving complete tumor regression in 80-100 % of mice. However, 2E'/PTX/CDN showed limited therapeutic efficacy with immune-cold B16F10 melanoma, accompanied by the increase of innate immune cells in the tumor draining lymph nodes peaking on day 5 post-administration and subsiding thereafter. The addition of a complex of 2E' and siRNA targeting PD-L1 (siPD-L1) at an optimal 5-d interval improved the response in B16F10 melanoma, resulting in tumor-free survival in 50 % of mice and rejection of live tumor rechallenge in 67 % of surviving animals. Consistent with the function of each component, the timed combination of 2E'/PTX/CDN and 2E'/siPD-L1 increased the fractions of mature dendritic cells and M1 macrophages, prevented the increase of regulatory T cells in tumor-draining lymph nodes, and increased melanoma antigen-specific CD8

Indexed as

ImmunotherapyMelanoma, ExperimentalPaclitaxelPancreatic NeoplasmsPolyethyleneimineAnimalsB7-H1 AntigenCell Line, TumorFemaleMiceMice, Inbred C57BLRNA, Small InterferingB7-H1 AntigenCd274 protein, mousePaclitaxelPolyethyleneimineRNA, Small InterferingChemoimmunotherapyDrug combinationImmunoactive nanocomplexInnate immune responseTreatment interval

Identifiers

PMID40023227
PMCPMC12002645

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.